Augmented rififylin is a risk factor linked to aberrant cardiomyocyte function, short-QT interval and hypertension Article (Faculty180)

cited authors

  • Gopalakrishnan, Kathirvel; Morgan, Eric E; Yerga-Woolwine, Shane; Farms, Phyllis; Kumarasamy, Sivarajan; Kalinoski, Andrea; Liu, Xiaochen; Wu, Jian; Liu, Lijun; Joe, Bina

start page

  • 764

end page

  • 71

volume

  • 57